{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:07:29Z","timestamp":1793833649027,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FHU InovPain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02444-6","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:06:38Z","timestamp":1783389998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry"],"prefix":"10.1186","volume":"27","author":[{"given":"S.","family":"Ferrao-Malheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jiacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43(4):3331024231159366. https:\/\/doi.org\/10.1177\/03331024231159366. Erratum in: Cephalalgia. 2024;44(6):3331024241255216. https:\/\/doi.org\/10.1177\/03331024241255216. PMID: 36855951","DOI":"10.1177\/03331024231159366"},{"key":"2444_CR2","doi-asserted-by":"publisher","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169. PMID: 36786548","DOI":"10.1177\/03331024231152169"},{"key":"2444_CR3","doi-asserted-by":"publisher","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294. https:\/\/doi.org\/10.1016\/S1474-4422(21)00409-9. Epub 2022 Jan 31. Erratum in: Lancet Neurol. 2022;21(10):e9. https:\/\/doi.org\/10.1016\/S1474-4422(22)00376-3. PMID: 35093196","DOI":"10.1016\/S1474-4422(21)00409-9"},{"issue":"1","key":"2444_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s10194-023-01698-8","volume":"24","author":"M Waliszewska-Pros\u00f3\u0142","year":"2023","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Vuralli D, Martelletti P (2023) What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain 24(1):163. https:\/\/doi.org\/10.1186\/s10194-023-01698-8. PMID: 38053061; PMCID: PMC10696682","journal-title":"J Headache Pain"},{"issue":"2","key":"2444_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Munaf\u00f2 A, Burgalassi A, De Cesaris F, Vigani G, Altamura C, Rivi V, Guerzoni S, Calabresi P, Raffaelli B, Iannone LF (2025) Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review. Headache 65(2):342\u2013352. https:\/\/doi.org\/10.1111\/head.14903. Epub 2025 Jan 17. PMID: 39825578","journal-title":"Headache"},{"key":"2444_CR6","doi-asserted-by":"publisher","unstructured":"Vikelis M, Rikos D, Argyriou AA, Dermitzakis EV, Andreou AP, Russo A (2025) Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis. Expert Rev Neurother 1\u201316. https:\/\/doi.org\/10.1080\/14737175.2025.2461766. Epub ahead of print. PMID: 39884968","DOI":"10.1080\/14737175.2025.2461766"},{"issue":"10","key":"2444_CR7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.neurol.2024.09.008","volume":"180","author":"X Moisset","year":"2024","unstructured":"Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P, Gu\u00e9gan-Massardier E, Lucas C, Mawet J, Valade D, Corand V, Gollion C, Moreau N, Grangeon L, Lant\u00e9ri-Minet M, Ducros A (2024) Migraine treatment: Position paper of the French Headache Society. Rev Neurol (Paris) 180(10):1087\u20131099 Epub 2024 Oct 15. PMID: 39406556","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"2444_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-023-01680-4","volume":"24","author":"M Lanteri-Minet","year":"2023","unstructured":"Lanteri-Minet M, Fabre R, Martin C, Pradat K, Alchaar A, Bozzolo E, Duchene ML, Van Obberghen EK, Donnet A, Fontaine D (2023) One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study. J Headache Pain 24(1):152. https:\/\/doi.org\/10.1186\/s10194-023-01680-4. PMID: 37940860; PMCID: PMC10633983","journal-title":"J Headache Pain"},{"issue":"2","key":"2444_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"RB Lipton","year":"2008","unstructured":"Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF, American Migraine Prevalence Prevention Advisory Group (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63(2):148\u2013158. https:\/\/doi.org\/10.1002\/ana.21211. PMID: 18059010; PMCID: PMC2729495","journal-title":"Ann Neurol"},{"key":"2444_CR10","doi-asserted-by":"publisher","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2009\u2013\u200974. https:\/\/doi.org\/10.1023\/a:1026119331193. PMID: 14651415","DOI":"10.1023\/a:1026119331193"},{"key":"2444_CR11","doi-asserted-by":"publisher","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2009\u2013\u200970. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x. PMID: 6880820","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2444_CR12","doi-asserted-by":"publisher","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88(1):41\u201352. https:\/\/doi.org\/10.1016\/S0304-3959(00)00305-5. PMID: 11098098","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"2444_CR13","doi-asserted-by":"publisher","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84(5):422\u2009\u2013\u200935. https:\/\/doi.org\/10.1016\/S0025-6196(11)60561-2. PMID: 19411439; PMCID: PMC2676125","DOI":"10.1016\/S0025-6196(11)60561-2"},{"key":"2444_CR14","doi-asserted-by":"publisher","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33(5):337\u2009\u2013\u200943. https:\/\/doi.org\/10.3109\/07853890109002087. PMID: 11491192","DOI":"10.3109\/07853890109002087"},{"key":"2444_CR15","doi-asserted-by":"crossref","unstructured":"Lundqvist C, Gossop M, Russell MB, Straand J, Kristoffersen ES (2019) Severity of Analgesic Dependence and Medication-overuse Headache. J Addict Med 13(5):346\u2013353 PMID: 30724760; PMCID: PMC6791494","DOI":"10.1097\/ADM.0000000000000504"},{"key":"2444_CR16","doi-asserted-by":"publisher","unstructured":"Williams DA, Robinson ME, Geisser ME (1994) Pain beliefs: assessment and utility. Pain 59(1):71\u201378. https:\/\/doi.org\/10.1016\/0304-3959(94)90049-3. PMID: 7854805","DOI":"10.1016\/0304-3959(94)90049-3"},{"issue":"4","key":"2444_CR17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1037\/1040-3590.7.4.524","volume":"7","author":"MJL Sullivan","year":"1995","unstructured":"Sullivan MJL, Bishop SR, Pivik J (1995) The Pain Catastrophizing Scale: Development and validation. Psychol Assess 7(4):524\u2013532. https:\/\/doi.org\/10.1037\/1040-3590.7.4.524","journal-title":"Psychol Assess"},{"issue":"6","key":"2444_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00415-025-13095-z","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Egeo G, Doretti A, d\u2019Onofrio F, Scatena P, Rinalduzzi S, Vinciguerra L, Sansone M, Vecchio R, Drago V, Viticchi G, Bartolini M, Ranieri A, Bandettini di Poggio M, Baldisseri F, Mascarella D, Brusaferri F, Caputi L, Messina S, Autunno M, Valenza A, Orlando B, Distefano M, Borrello L, Pistoia F, Camarda C, Saporito G, Querzola G, Torelli P, Salerno A, Gragnani F, Petolicchio B, Carnevale A, Messina R, Filippi M, Tavani S, Fiorentini G, Bonassi S, Cevoli S, Mannocci A (2025) Italian Migraine Registry (I-GRAINE) study group. A 24-week prospective, multicenter, real-world study on eptinezumab\u2019s effectiveness and safety in migraine prevention (EMBRACE II). J Neurol 272(6):382. https:\/\/doi.org\/10.1007\/s00415-025-13095-z. PMID: 40332560; PMCID: PMC12058817","journal-title":"J Neurol"},{"issue":"2","key":"2444_CR19","doi-asserted-by":"publisher","first-page":"333102425141465","DOI":"10.1177\/03331024251414659","volume":"46","author":"LF Iannone","year":"2026","unstructured":"Iannone LF, Piella EM, Montisano DA, Fasano C, Sebastianelli G, Coppola G, Ferrandi D, Lanni C, Prudenzano MP, de Tommaso M, Merlo P, De Cesaris F, Chiarugi A, Munaf\u00f2 A, Pistoia F, Ornello R, Doretti A, Grazzi L, Lo Castro F, De Icco R, Vaghi G, Avino G, Romozzi M, Calabresi P, Battistini S, Rufa A, Albanese M, Trimboli M, Carlucci G, Silvestro M, Russo A, Rainero I, Valente MR, Fofi L, Marcosano M, Geppetti P, Altamura C, Vernieri F, Tassorelli C, Sacco S, Guerzoni S (2026) Italian Headache Registry (RICe) Study Group. Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study). Cephalalgia 46(2):3331024251414659. https:\/\/doi.org\/10.1177\/03331024251414659. Epub 2026 Feb 12. PMID: 41684106","journal-title":"Cephalalgia"},{"issue":"1","key":"2444_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-026-02275-5","volume":"27","author":"EV Dermitzakis","year":"2026","unstructured":"Dermitzakis EV, Argyriou AA, Chondrogianni M, Foska A, Rikos D, Athanasopoulos D, Tsironis C, Soldatos P, Koutsokera M, Tsitsaras N, Litsardopoulos P, Mavraki E, Vikelis M, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group (2026) Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group. J Headache Pain 27(1):48. https:\/\/doi.org\/10.1186\/s10194-026-02275-5. PMID: 41578184; PMCID: PMC12918022","journal-title":"J Headache Pain"},{"issue":"1","key":"2444_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s10194-025-02180-3","volume":"26","author":"AP Andreou","year":"2025","unstructured":"Andreou AP, Hill B, Al-Rawi R, Murphy M, Soares I, Briscoe J, Kilner R, Lambru G (2025) A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience. J Headache Pain 26(1):235. https:\/\/doi.org\/10.1186\/s10194-025-02180-3. PMID: 41168777; PMCID: PMC12573807","journal-title":"J Headache Pain"},{"issue":"1","key":"2444_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/neurolint16010019","volume":"16","author":"R Suliman","year":"2024","unstructured":"Suliman R, Santos V, Al Qaisi I, Aldaher B, Al Fardan A, Al Barrawy H, Bader Y, Supena JL, Alejandro K, Alsaadi T (2024) Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study. Neurol Int 16(1):274\u2013288. https:\/\/doi.org\/10.3390\/neurolint16010019. PMID: 38392960; PMCID: PMC10893254","journal-title":"Neurol Int"},{"issue":"1","key":"2444_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-024-01788-1","volume":"25","author":"A Scheffler","year":"2024","unstructured":"Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, Nsaka M, Lindner D, Naegel S, Burow P, Fleischmann R, Holle D (2024) Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany. J Headache Pain 25(1):79. https:\/\/doi.org\/10.1186\/s10194-024-01788-1. PMID: 38755541; PMCID: PMC11097519","journal-title":"J Headache Pain"},{"issue":"1","key":"2444_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-024-01790-7","volume":"25","author":"JB Hong","year":"2024","unstructured":"Hong JB, Israel-Willner H, Peikert A, Schanbacher P, Tozzi V, K\u00f6chling M, Reuter U, Raffaelli B, NTD Study Group (2024) Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry. J Headache Pain 25(1):90. https:\/\/doi.org\/10.1186\/s10194-024-01790-7. PMID: 38825722; PMCID: PMC11145812","journal-title":"J Headache Pain"},{"issue":"7","key":"2444_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response. Pharmaceuticals (Basel) 16(7):934. https:\/\/doi.org\/10.3390\/ph16070934. PMID: 37513846; PMCID: PMC10385131","journal-title":"Pharmaceuticals (Basel)"},{"key":"2444_CR26","doi-asserted-by":"publisher","unstructured":"Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19\u201326. https:\/\/doi.org\/10.1002\/ana.10786. PMID: 14705108","DOI":"10.1002\/ana.10786"},{"issue":"3","key":"2444_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144(3):325\u2013333. https:\/\/doi.org\/10.1111\/ane.13472. Epub 2021 May 21. PMID: 34019304; PMCID: PMC8453754","journal-title":"Acta Neurol Scand"},{"key":"2444_CR28","doi-asserted-by":"publisher","unstructured":"Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22(1):114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4. Erratum in: J Headache Pain. 2021;22(1):131. https:\/\/doi.org\/10.1186\/s10194-021-01342-3. PMID: 34600468; PMCID: PMC8487575","DOI":"10.1186\/s10194-021-01333-4"},{"issue":"8","key":"2444_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/head.14624","volume":"63","author":"O Zamir","year":"2023","unstructured":"Zamir O, Yarns BC, Lagman-Bartolome AM, Jobanputra L, Lawler V, Lay C (2023) Understanding the gaps in headache and migraine treatment with psychological and behavioral interventions: A narrative review. Headache 63(8):1031\u20131039. https:\/\/doi.org\/10.1111\/head.14624. Epub 2023 Aug 28. PMID: 37638484","journal-title":"Headache"},{"key":"2444_CR30","doi-asserted-by":"publisher","unstructured":"Basedau H, Ornello R, Matteis E, Davaasuren B, Kadyrova B, Vuralli D, Bozhenko M, Azizova I, Bitsadze N, Eralieva E, Ashina M, Mitsikostas D, Puledda F (2023) Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects? Cephalalgia 43(12):3331024231218392. https:\/\/doi.org\/10.1177\/03331024231218392. PMID: 38041833","DOI":"10.1177\/03331024231218392"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02444-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:51:18Z","timestamp":1790841078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02444-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9763217\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This observational study did not require approval from an ethics committee. It was conducted as part of the FHU InovPain registry clinical research program, which received authorization from the French National Commission on Informatics and Liberty (Commission Nationale de l\u2019Informatique et des Libert\u00e9s [CNIL]; CIL register no. 278, dated 11\/09\/2017). Patients were included only after providing written informed consent allowing their data recorded in the FHU InovPain registry database to be used for clinical research purposes.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SFM has no conflict of interest. RF had no conflict of interest. TJ had no conflict of interest. MLM received personal fees for consultancy activities from: Abbvie\/Allergan, Amgen, Eli Lilly, IPSEN, Lundbeck, Medtronic, Novartis, Orion Pharma, Perfood, Pfizer, Reckitt-Benckiser, Savia, Bioelectronics, Teva, UPSA. MLM is also an Associate Editor of the journal and did not take part in, any review or editorial decision-making process related to this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"231"}}